Ana Beatriz Vargas-Santos

Dr. Ana Beatriz Vargas-Santos

Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
Ana Beatriz Vargas-SantosAna Beatriz Vargas-Santos
Ana Beatriz Vargas-Santos
TNTuhina Neogi
Tuhina Neogi

16 March 2015 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
WTWilliam J. Taylor
William J. Taylor
JFJaap Fransen
Jaap Fransen
TJTim L. Jansen
Tim L. Jansen
NDNicola Dalbeth
Nicola Dalbeth
HSH. Ralph Schumacher
H. Ralph Schumacher
TNTuhina Neogi
Tuhina Neogi
Objective: To determine which clinical, laboratory, and imaging features most accurately distinguished gout from non‐gout.Methods: We performed a cross‐sectional study of consecutive rheumatology clinic patients with ≥1 swollen joint or subcutaneous tophus. Gout was defined by synovial fluid or tophus aspirate microscopy by certified examiners in all patients. The sample was randomly divided into a model development (two‐thirds) and test sample (one‐third). Univariate and multivariate association between clinical features and monosodium urate–defined gout was determined using logistic regression modeling. Shrinkage of regression weights was performed to prevent overfitting of the final model. Latent class analysis was conducted to identify patterns of joint involvement.Results: In total, 983 patients were included. Gout was present in 509 (52%). In the development sample (n = 653), the following features were selected for the final model: joint erythema (multivariate odds ratio [OR] 2.13), difficulty walking (multivariate OR 7.34), time to maximal pain 6 mg/dl (0.36 mmoles/liter; multivariate OR 3.35), ultrasound double contour sign (multivariate OR 7.23), and radiograph erosion or cyst (multivariate OR 2.49). The final model performed adequately in the test set, with no evidence of misfit, high discrimination, and predictive ability. MTP1 joint involvement was the most common joint pattern (39.4%) in gout cases.Conclusion: Ten key discriminating features have been identified for further evaluation for new gout classification criteria. Ultrasound findings and degree of uricemia add discriminating value, and will significantly contribute to more accurate classification criteria.

9 September 2019 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
DBDavid Bursill
David Bursill
WTWilliam J Taylor
William J Taylor
RTRobert Terkeltaub
Robert Terkeltaub
AAAbhishek Abhishek
Abhishek Abhishek
ASAlexander K So
Alexander K So
NDNicola Dalbeth
Nicola Dalbeth
Objective There is a lack of standardisation in the terminology used to describe gout. The aim of this project was to develop a consensus statement describing the recommended nomenclature for disease states of gout. Methods A content analysis of gout-related articles from rheumatology and general internal medicine journals published over a 5-year period identified potential disease states and the labels commonly assigned to them. Based on these findings, experts in gout were invited to participate in a Delphi exercise and face-to-face consensus meeting to reach agreement on disease state labels and definitions. Results The content analysis identified 13 unique disease states and a total of 63 unique labels. The Delphi exercise (n=76 respondents) and face-to-face meeting (n=35 attendees) established consensus agreement for eight disease state labels and definitions. The agreed labels were as follows: ‘asymptomatic hyperuricaemia’, ‘asymptomatic monosodium urate crystal deposition’, ‘asymptomatic hyperuricaemia with monosodium urate crystal deposition’, ‘gout’, ‘tophaceous gout’, ‘erosive gout’, ‘first gout flare’ and ‘recurrent gout flares’. There was consensus agreement that the label ‘gout’ should be restricted to current or prior clinically evident disease caused by monosodium urate crystal deposition (gout flare, chronic gouty arthritis or subcutaneous tophus). Conclusion Consensus agreement has been established for the labels and definitions of eight gout disease states, including ‘gout’ itself. The Gout, Hyperuricaemia and Crystal-Associated Disease Network recommends the use of these labels when describing disease states of gout in research and clinical practice.

21 November 2017 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
AGAngelo L. Gaffo
Angelo L. Gaffo
NDNicola Dalbeth
Nicola Dalbeth
KSKenneth G. Saag
Kenneth G. Saag
JSJasvinder Singh
Jasvinder Singh
ERElizabeth J. Rahn
Elizabeth J. Rahn
WTWilliam Taylor
William Taylor
Objective: To perform external validation of a provisional definition of disease flare in patients with gout.Methods: Five hundred nine patients with gout were enrolled in a cross‐sectional study during a routine clinical care visit at 17 international sites. Data were collected to classify patients as experiencing or not experiencing a gout flare, according to a provisional definition. A local expert rheumatologist performed the final independent adjudication of gout flare status. Sensitivity, specificity, predictive values, and receiver operating characteristic (ROC) curves were used to determine the diagnostic performance of gout flare definitions.Results: The mean ± SD age of the patients was 57.5 ± 13.9 years, and 89% were male. The definition requiring fulfillment of at least 3 of 4 criteria (patient‐defined gout flare, pain at rest score of >3 on a 0–10‐point numerical rating scale, presence of at least 1 swollen joint, and presence of at least 1 warm joint) was 85% sensitive and 95% specific in confirming the presence of a gout flare, with an accuracy of 92%. The ROC area under the curve was 0.97. The definition based on a classification and regression tree algorithm (entry point, pain at rest score >3, followed by patient‐defined flare “yes”) was 73% sensitive and 96% specific.Conclusion: The definition of gout flare that requires fulfillment of at least 3 of 4 patient‐reported criteria is now validated to be sensitive, specific, and accurate for gout flares, as demonstrated using an independent large international patient sample. The availability of a validated gout flare definition will improve the ascertainment of an important clinical outcome in studies of gout.

1 March 2019 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
DBDavid Bursill
David Bursill
WTWilliam J. Taylor
William J. Taylor
RTRobert Terkeltaub
Robert Terkeltaub
Masanari KuwabaraMasanari Kuwabara
Masanari Kuwabara
TMTony R. Merriman
Tony R. Merriman
NDNicola Dalbeth
Nicola Dalbeth

30 July 2021 in Nature Reviews Rheumatology
Verified
Journal Article
Open access
PDF file
LSLisa Stamp
Lisa Stamp
HFHamish Farquhar
Hamish Farquhar
HPHuai Leng Pisaniello
Huai Leng Pisaniello
Ana Beatriz Vargas-SantosAna Beatriz Vargas-Santos
Ana Beatriz Vargas-Santos
MFMark Fisher
Mark Fisher
AGAngelo L. Gaffo
Angelo L. Gaffo
Gout and chronic kidney disease (CKD) frequently coexist, but quality evidence to guide gout management in people with CKD is lacking. Use of urate-lowering therapy (ULT) in the context of advanced CKD varies greatly, and professional bodies have issued conflicting recommendations regarding the treatment of gout in people with concomitant CKD. As a result, confusion exists among medical professionals about the appropriate management of people with gout and CKD. This Consensus Statement from the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) discusses the evidence and/or lack thereof for the management of gout in people with CKD and identifies key areas for research to address the challenges faced in the management of gout and CKD. These discussions, which address areas for research both in general as well as related to specific medications used to treat gout flares or as ULT, are supported by separately published G-CAN systematic literature reviews. This Consensus Statement is not intended as a guideline for the management of gout in CKD; rather, it analyses the available literature on the safety and efficacy of drugs used in gout management to identify important gaps in knowledge and associated areas for research.